Literature DB >> 18662554

Three-dimensional imaging-based radiobiological dosimetry.

George Sgouros1, Eric Frey, Richard Wahl, Bin He, Andrew Prideaux, Robert Hobbs.   

Abstract

Targeted radionuclide therapy holds promise as a new treatment for cancer. Advances in imaging are making it possible for researchers to evaluate the spatial distribution of radioactivity in tumors and normal organs over time. Matched anatomical imaging, such as combined single-photon emission computed tomography/computed tomography and positron emission tomography/computed tomography, has also made it possible to obtain tissue density information in conjunction with the radioactivity distribution. Coupled with sophisticated iterative reconstruction algorithms, these advances have made it possible to perform highly patient-specific dosimetry that also incorporates radiobiological modeling. Such sophisticated dosimetry techniques are still in the research investigation phase. Given the attendant logistical and financial costs, a demonstrated improvement in patient care will be a prerequisite for the adoption of such highly-patient specific internal dosimetry methods.

Entities:  

Mesh:

Year:  2008        PMID: 18662554      PMCID: PMC2597292          DOI: 10.1053/j.semnuclmed.2008.05.008

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  96 in total

1.  Is radiation nephropathy caused by yttrium-90?

Authors:  Andreas Otte; Stefan M Weiner; Markus Cybulla
Journal:  Lancet       Date:  2002-03-16       Impact factor: 79.321

2.  Efficient simulation of SPECT down-scatter including photon interactions with crystal and lead.

Authors:  Hugo W A M de Jong; Wen-Tung Wang; Eric C Frey; Max A Viergever; Freek J Beekman
Journal:  Med Phys       Date:  2002-04       Impact factor: 4.071

Review 3.  Targeted therapy of cancer with radiolabeled antibodies.

Authors:  David M Goldenberg
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

Review 4.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

5.  Model prediction of treatment planning for dose-fractionated radioimmunotherapy.

Authors:  Sui Shen; Jun Duan; Ruby F Meredith; Donald J Buchsbaum; Ivan A Brezovich; Prem N Pareek; James A Bonner
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

6.  Rationales, evidence, and design considerations for fractionated radioimmunotherapy.

Authors:  Gerald L DeNardo; Jeffery Schlom; Donald J Buchsbaum; Ruby F Meredith; Joseph A O'Donoghue; George Sgouros; John L Humm; Sally J DeNardo
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

7.  166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.

Authors:  Sergio Giralt; William Bensinger; Mark Goodman; Donald Podoloff; Janet Eary; Richard Wendt; Raymond Alexanian; Donna Weber; David Maloney; Leona Holmberg; Joseph Rajandran; Hazel Breitz; Richard Ghalie; Richard Champlin
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

8.  Application of the linear-quadratic model to combined modality radiotherapy.

Authors:  Rachel K Bodey; Phil M Evans; Glenn D Flux
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

9.  Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.

Authors:  Hazel Breitz; Richard Wendt; Michael Stabin; Lionel Bouchet; Barry Wessels
Journal:  Cancer Biother Radiopharm       Date:  2003-04       Impact factor: 3.099

10.  Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.

Authors:  George Sgouros; Katherine S Kolbert; Arif Sheikh; Keith S Pentlow; Edward F Mun; Axel Barth; Richard J Robbins; Steven M Larson
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

View more
  29 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

2.  A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging.

Authors:  Xing Rong; Yong Du; Eric C Frey
Journal:  Phys Med Biol       Date:  2012-05-23       Impact factor: 3.609

3.  Development and evaluation of an improved quantitative (90)Y bremsstrahlung SPECT method.

Authors:  Xing Rong; Yong Du; Michael Ljungberg; Erwann Rault; Stefaan Vandenberghe; Eric C Frey
Journal:  Med Phys       Date:  2012-05       Impact factor: 4.071

4.  A collimator optimization method for quantitative imaging: application to Y-90 bremsstrahlung SPECT.

Authors:  Xing Rong; Eric C Frey
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

5.  Radiopharmaceutical therapy in the era of precision medicine.

Authors:  George Sgouros; David M Goldenberg
Journal:  Eur J Cancer       Date:  2014-06-19       Impact factor: 9.162

6.  Radiopharmaceutical Therapy.

Authors:  George Sgouros
Journal:  Health Phys       Date:  2019-02       Impact factor: 1.316

7.  PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms.

Authors:  Lukas M Carter; Troy M Crawford; Tatsuhiko Sato; Takuya Furuta; Chansoo Choi; Chan Hyeong Kim; Justin L Brown; Wesley E Bolch; Pat B Zanzonico; Jason S Lewis
Journal:  J Nucl Med       Date:  2019-06-14       Impact factor: 10.057

8.  What You See Is Not What You Get: On the Accuracy of Voxel-Based Dosimetry in Molecular Radiotherapy.

Authors:  Johannes Tran-Gia; Maikol Salas-Ramirez; Michael Lassmann
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 10.057

9.  Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent.

Authors:  Donika Plyku; Esther Mena; Steven P Rowe; Martin A Lodge; Zsolt Szabo; Steve Y Cho; Martin G Pomper; George Sgouros; Robert F Hobbs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236

10.  124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison.

Authors:  Robert F Hobbs; Richard L Wahl; Martin A Lodge; Mehrbod S Javadi; Steve Y Cho; David T Chien; Marge E Ewertz; Caroline E Esaias; Paul W Ladenson; George Sgouros
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.